ClinicalTrials.gg
Drug

Lapatinib clinical trials

Also written Tykerb, GW-572016, GSK572016 and Tyverb.

studies test it
194
open now
0
in phase 3
24
first study started
2002

How each study uses Lapatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
13 Mar 2007 · TYKERB · NDA 022059 (FDA, Drugs@FDA)
European Union
10 Jun 2008 · Tyverb · EMEA/H/C/000795 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lapatinib
131
lapatinib ditosylate
39
Lapatinib oral tablets
3
lapatinib (GW572016)
3
Lapatinib (GW572016) oral tablets
2

Brand

Tykerb
64
Tyverb
16

Development codes

GW-572016
36
GSK572016
21
GW2016
21

In one entry with another drug

Given together, or one or the other

Lapatinib and Paclitaxel
2
Lapatinib and Capecitabine
2
Lapatinib, Vinorelbine
2

Studies by the year they started

194 studies that test it; most in 2009 (26)

Studies that test Lapatinib, by start year
YearStudies
20021
20033
200417
200518
200618
200724
200820
200926
201013
201120
201212
201311
20146
20151
20162
20211
20231

By phase

A phase 1/2 study counts in both.

Early Phase 1
4
Phase 1
56
Phase 2
123
Phase 3
24
Phase 4
1
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 65 · Other 129

GlaxoSmithKline (45) · National Cancer Institute (NCI) (22) · Novartis Pharmaceuticals (17) · UNC Lineberger Comprehensive Cancer Center (4) · M.D. Anderson Cancer Center (4) · Cancer Trials Ireland (3) · UNICANCER (3) · Georgetown University (3)

Often tested with

Tested in the same studies.

Paclitaxel (18) · Trastuzumab (17) · Capecitabine (17) · Vinorelbine (8) · Everolimus (5) · Pazopanib (5) · Carboplatin (4) · Erlotinib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Lapatinib is the comparator. A study of two new drugs counts under both.

Studies

Open first, then newest update. How each study uses Lapatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 194

See all 194 studies that test Lapatinib →

Given beside what is tested · 45 — Lapatinib is usual care or a partner of the new treatment

Showing 20 of 45.

As the comparator · 15 — what is tested is compared with Lapatinib

Codes

What other systems call Lapatinib · ClinicalTrials.gg INT006708

  • MeSH (NLM) D000077341LapatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 0VUA21238FLAPATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 480167Confirmed FDA, Wikidata
  • Wikidata Q420323lapatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C26653LapatinibOne source FDA
  • DrugBank DB01259One source Wikidata

Also registered as lapatinib ditosylate (UNII G873GX646R · RxNorm 481474).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.